donepezil and Nausea
donepezil has been researched along with Nausea in 14 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 9.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "Sustained-release, high-dose (23 mg/d) donepezil has been approved for treatment of moderate to severe Alzheimer disease (AD)." | 5.24 | Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index. ( Bae, JN; Carroll, BJ; Han, C; Jung, YE; Kang, HS; Kim, BJ; Kim, BS; Kim, DK; Kim, JL; Kim, KW; Kim, SG; Kim, SY; Kim, YH; Lee, C; Lee, DW; Lee, JY; Lee, K; Lee, SY; Lee, YM; Moon, SW; Myung, W; Ryu, SH; Shin, IS; Yu, H, 2017) |
| "Donepezil, an acetylcholinesterase inhibitor, is associated with gastrointestinal symptoms, such as nausea, vomiting, and anorexia, which may affect adherence to continuous therapy." | 4.12 | Effects of Rikkunshi-To, a Japanese kampo medicine, on donepezil-induced gastrointestinal side effects in mice. ( Hagihara, K; Jotaki, A; Kirikihira, K; Michihara, A; Miyake, Y; Sato, Y; Yamamoto, K, 2022) |
| " There were 2 cases of adverse reaction of increased stool frequency in GV-971 (5." | 3.11 | Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease. ( Lin, PX; Xue, LH; Zhang, LF; Zhang, YP, 2022) |
| " Experiment 1 tested the effects of 5 mg/per day dosage on cognitive and EEG markers at 6-hour, 2-week and 4-week follow-ups." | 2.76 | Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers. ( Balsters, JH; Bokde, AL; Brennan, S; Cassidy, SM; Delmonte, S; Fagan, AJ; Galli, A; Kilcullen, SM; Lai, R; Laruelle, M; Lawlor, B; Martin, MP; Meaney, JF; O'Connell, RG; Robertson, IH; Upton, N, 2011) |
| " Adverse events (AEs) were recorded throughout." | 2.75 | Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. ( Doody, RS; Ferris, S; Gao, J; Goldman, R; Murthy, AK; Salloway, S, 2010) |
| "Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer's Disease Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: donepezil 5 mg/d, -1." | 2.71 | Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. ( Black, S; Burns, A; Geldmacher, DS; Hecker, J; Kumar, D; Perdomo, C; Pratt, R; Román, GC; Salloway, S, 2003) |
| "Donepezil (Aricept) is a highly selective acetylcholinesterase inhibitors with a pharmacokinetic profile allowing once-daily dosing." | 2.42 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions. ( Geldmacher, DS, 2004) |
| "Donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (AChE) for the treatment of mild to moderate dementia associated with Alzheimer's disease." | 2.40 | Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. ( Shintani, EY; Uchida, KM, 1997) |
| " The adverse drug effects and discontinuation rates were investigated with self-reported complaint after starting or increasing anti-dementia drugs." | 1.48 | Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia. ( Cho, AH; Kim, JS; Lim, EY; Yang, DW, 2018) |
| "The objective was to investigate the frequency of adverse events (AE) as a cause for discontinuation of donepezil treatment for Alzheimer's dementia (DAT) in a geriatric memory unit." | 1.35 | [Adverse events causing discontinuation of donepezil for Alzheimer's dementia]. ( Carøe, TK; Moe, C, 2009) |
| "Donepezil is an acetylcholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate Alzheimer's disease." | 1.31 | Adverse effects associated with the use of donepezil in general practice in England. ( Dunn, NR; Pearce, GL; Shakir, SA, 2000) |
Research
Studies (14)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Zhang, LF | 1 |
| Zhang, YP | 1 |
| Lin, PX | 1 |
| Xue, LH | 1 |
| Yamamoto, K | 1 |
| Sato, Y | 1 |
| Hagihara, K | 1 |
| Kirikihira, K | 1 |
| Jotaki, A | 1 |
| Michihara, A | 1 |
| Miyake, Y | 1 |
| Lee, C | 1 |
| Lee, K | 1 |
| Yu, H | 1 |
| Ryu, SH | 1 |
| Moon, SW | 1 |
| Han, C | 1 |
| Lee, JY | 1 |
| Lee, YM | 1 |
| Kim, SG | 1 |
| Kim, KW | 1 |
| Lee, DW | 1 |
| Kim, SY | 2 |
| Lee, SY | 1 |
| Bae, JN | 1 |
| Jung, YE | 1 |
| Kim, JL | 1 |
| Kim, BS | 1 |
| Shin, IS | 1 |
| Kim, YH | 1 |
| Kim, BJ | 1 |
| Kang, HS | 1 |
| Myung, W | 1 |
| Carroll, BJ | 1 |
| Kim, DK | 1 |
| Lim, EY | 1 |
| Yang, DW | 1 |
| Kim, JS | 1 |
| Cho, AH | 1 |
| Han, SH | 1 |
| Lee, JH | 1 |
| Park, KW | 1 |
| Chen, C | 1 |
| Tripathi, M | 1 |
| Dash, A | 1 |
| Kubota, N | 1 |
| Doody, RS | 1 |
| Ferris, S | 1 |
| Salloway, S | 2 |
| Goldman, R | 1 |
| Gao, J | 1 |
| Murthy, AK | 1 |
| Carøe, TK | 1 |
| Moe, C | 1 |
| Balsters, JH | 1 |
| O'Connell, RG | 1 |
| Martin, MP | 1 |
| Galli, A | 1 |
| Cassidy, SM | 1 |
| Kilcullen, SM | 1 |
| Delmonte, S | 1 |
| Brennan, S | 1 |
| Meaney, JF | 1 |
| Fagan, AJ | 1 |
| Bokde, AL | 1 |
| Upton, N | 1 |
| Lai, R | 1 |
| Laruelle, M | 1 |
| Lawlor, B | 1 |
| Robertson, IH | 1 |
| Heller, JH | 1 |
| Spiridigliozzi, GA | 1 |
| Sullivan, JA | 1 |
| Doraiswamy, PM | 1 |
| Krishnan, RR | 1 |
| Kishnani, PS | 1 |
| Black, S | 1 |
| Román, GC | 1 |
| Geldmacher, DS | 2 |
| Hecker, J | 1 |
| Burns, A | 1 |
| Perdomo, C | 1 |
| Kumar, D | 1 |
| Pratt, R | 1 |
| Shintani, EY | 1 |
| Uchida, KM | 1 |
| Dunn, NR | 1 |
| Pearce, GL | 1 |
| Shakir, SA | 1 |
| Lam, W | 1 |
Reviews
2 reviews available for donepezil and Nausea
| Article | Year |
|---|---|
Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.
Topics: Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorder | 2004 |
Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Diarrhea; Donepezil; Drug Administrati | 1997 |
Trials
7 trials available for donepezil and Nausea
| Article | Year |
|---|---|
Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Humans; Ions; Nausea; Sodium | 2022 |
Adverse Events With Sustained-Release Donepezil in Alzheimer Disease: Relation to Body Mass Index.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Body Weight; Chol | 2017 |
Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cholinesterase Inhibitors; Donepezil; Dose | 2017 |
Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
Topics: Adult; Aged; Aged, 80 and over; Amnesia; Cholinesterase Inhibitors; Cognition Disorders; Diarrhea; D | 2010 |
Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Cognition; Cross-Over Studies; Diarrhea; Done | 2011 |
Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.
Topics: Adult; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil; Dose-Response Relationship, Drug; D | 2003 |
Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Cardiovascular System; Cholinesterase Inhibitor | 2003 |
Other Studies
5 other studies available for donepezil and Nausea
| Article | Year |
|---|---|
Effects of Rikkunshi-To, a Japanese kampo medicine, on donepezil-induced gastrointestinal side effects in mice.
Topics: Acetylcholinesterase; Animals; Anorexia; Donepezil; Drugs, Chinese Herbal; Ghrelin; Humans; Kaolin; | 2022 |
Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Donepezil; Exanthema; Female; Huma | 2018 |
[Adverse events causing discontinuation of donepezil for Alzheimer's dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Appetite; Cholinesterase Inhibitors; Diarrhea; Donepezil | 2009 |
Adverse effects associated with the use of donepezil in general practice in England.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Drug Prescriptions; E | 2000 |
Pharmacological treatment of cognitive deficits in Alzheimer's disease.
Topics: Alzheimer Disease; Diarrhea; Donepezil; Humans; Indans; Nausea; Nootropic Agents; Piperidines; Vomit | 2002 |